|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| A61K 39/39 | |||
| A61P 35/00 | |||
| A61P 37/02 |
| (11) | Patento numeris | 3177321 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15829910.7 |
| Europos patento paraiškos padavimo data | 2015-08-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-06-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-11-25 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CA2015/050747 |
| Data | 2015-08-07 |
| (87) | Numeris | WO 2016/019472 |
| Data | 2016-02-11 |
| (30) | Numeris | Data | Šalis |
| 201462034915 P | 2014-08-08 | US |
| (72) |
MADIYALAKAN, Ragupathy, CA
NICODEMUS, Christopher F., US
|
| (73) |
Oncoquest Pharmaceuticals Inc.,
670-21 Sannae-ro, Sannae-myeon, Miryang-Si,
KR
|
| (54) | TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER |
| TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER |